2026-11-10 15:28:43 UTC#609393duplicateconfirmednews
Johnson & Johnson (JNJ) stock news
Johnson & Johnson (JNJ) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-11-10 14:11:42 UTC#608803duplicateconfirmednews
Johnson & Johnson plans FDA submission for Caplyta in bipolar mania following positive Phase 3 trial results
2026-11-10 13:21:29 UTC#608289duplicateconfirmednews
Johnson & Johnson reports positive Phase 3 data for Caplyta in bipolar mania
2026-11-10 13:00:00 UTC#608158newconfirmedpress release
Johnson & Johnson reports positive Phase 3 results for CAPLYTA in bipolar mania, plans FDA submission
yahooimportance 0.60trust 1.00Johnson & Johnson +0.60CAPLYTA +0.60Food and Drug Administration +0.30+2 entities
2026-11-10 11:06:06 UTC#607338newconfirmednews
iShares MSCI USA Momentum Factor ETF (MTUM) reports $178.4M net inflow on Nov. 6, led by AMD and Micron buys
yahooimportance 0.30trust 0.60iShares MSCI USA Momentum Factor ETF +0.20Advanced Micro Devices, Inc. +0.30Micron Technology, Inc. +0.30+1 entities
2026-11-09 20:12:00 UTC#602823duplicateconfirmednews
Delix Therapeutics Secures $100 Million in Series C Funding Led by J&J and Dementia Discovery Fund
dow_jonesimportance 0.30trust 0.90Johnson & Johnson +0.20Delix Therapeutics +0.40JJDC Inc. +0.20+2 entities
2026-11-09 17:12:25 UTC#601970duplicateconfirmednews
Johnson & Johnson invests in Delix Therapeutics for non-hallucinogenic psychedelic depression treatments
2026-11-09 16:36:00 UTC#601758newconfirmednews
Healthcare sector stocks rise amid Medicare Open Enrollment; JNJ, VRTX, HUM, EW, and MCK in focus
yahooimportance 0.30trust 0.50Johnson & Johnson +0.20Vertex Pharmaceuticals Incorporated +0.20Humana Inc. +0.20+2 entities
2026-11-09 11:03:43 UTC#599333newconfirmednews
Johnson & Johnson (JNJ) records $68.4 million in net ETF selling on Nov. 5, led by DIA outflows
yahooimportance 0.30trust 0.60Johnson & Johnson -0.30SPDR Dow Jones Industrial Average ETF Trust -0.30
2026-11-08 21:56:59 UTC#596706duplicateconfirmednews
J&J prostate cancer combination study results reported; PSA levels lowered in early trial
2026-11-08 16:00:00 UTC#596150newconfirmedpress release
Johnson & Johnson reports 73% PSA response rate for pasritamig and JNJ-9401 combination in advanced prostate cancer
pr newswireimportance 0.50trust 0.90Johnson & Johnson +0.50pasritamig +0.60JNJ-9401 +0.60+2 entities
2026-11-08 03:13:19 UTC#595368duplicateconfirmednews
Johnson & Johnson reports positive clinical trial results for Icotrokinra in psoriatic arthritis patients
2026-11-08 03:07:23 UTC#595364duplicateconfirmednews
Johnson & Johnson releases additional Phase 2 nipocalimab data for Sjögren's disease
2026-11-07 15:40:10 UTC#594738duplicateconfirmednews
Johnson & Johnson reports positive Phase 3 trial results for psoriatic arthritis pill
2026-11-07 15:08:35 UTC#594693duplicateconfirmednews
Johnson & Johnson's once-daily pill Icotyde shows efficacy in Phase 3 psoriatic arthritis trial
2026-11-07 15:03:00 UTC#594685duplicateconfirmedpress release
Johnson & Johnson Phase 3 data shows 58% ACR20 response for ICOTYDE in psoriatic arthritis
yahooimportance 0.40trust 0.90Johnson & Johnson +0.50icotrokinra +0.60American College of Rheumatology 0
2026-11-07 15:03:00 UTC#594684duplicateconfirmedpress release
Johnson & Johnson shares Phase 2 DAHLIAS study patient insights for nipocalimab in Sjögren's disease
yahooimportance 0.30trust 0.90Johnson & Johnson +0.40nipocalimab +0.40Sjögren's disease +0.40+2 entities
2026-11-07 15:03:00 UTC#594676duplicateconfirmedpress release
Johnson & Johnson reports Phase 3 ICOTYDE psoriatic arthritis data showing 58% ACR20 response at Week 16
pr newswireimportance 0.30trust 0.90Johnson & Johnson +0.40ICOTYDE +0.50American College of Rheumatology 0
2026-11-07 15:03:00 UTC#594675newconfirmedpress release
Johnson & Johnson reports Phase 2 nipocalimab data in Sjögren's disease showing symptom improvement insights
pr newswireimportance 0.40trust 0.90Johnson & Johnson +0.30nipocalimab +0.40Sjögren's disease +0.30+1 entities
2026-11-07 15:00:00 UTC#594658newconfirmednews